BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study.

Raffaele Pellegrino Gianluca PellinoLucio SelvaggiFrancesco Selvaggi Alessandro Federico Marco Romano Antonietta Gerarda Gravina

Published in: Expert review of clinical pharmacology (2022)

This vaccine was safe in a population of patients with inflammatory bowel disease and, therefore, could be safely administered in this clinical setting.

Keyphrases

patients with inflammatory bowel disease
end stage renal disease
coronavirus disease
sars cov
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
patient reported outcomes
smoking cessation
replacement therapy